Drug
Gp2411
Gp2411: highest development phase Phase 3, developed by Sandoz. 1 trial record tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Sandoz
Trials
| Drug | Phase | Indication |
|---|---|---|
| GP2411 NCT03974100 | Phase 3 | Postmenopausal Women With Osteoporosis |
Latest
No recent events.
Follow Gp2411 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.